Entrada Therapeutics (TRDA) Accounts Payables (2020 - 2026)

Entrada Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 33.91% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 33.91% YoY), while the FY2025 annual figure was $2.3 million, down 46.25% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.9 million, up from $2.3 million in the prior quarter.
• The five-year high for Accounts Payables was $6.5 million in Q1 2023, with the low at $752000.0 in Q3 2023.
• The 5-year median for Accounts Payables is $2.5 million (2024), against an average of $2.9 million.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 748.44% in 2022, then sank 60.97% in 2024.
• Entrada Therapeutics' Accounts Payables stood at $6.0 million in 2022, then tumbled by 45.29% to $3.3 million in 2023, then rose by 29.97% to $4.3 million in 2024, then plunged by 46.25% to $2.3 million in 2025, then grew by 28.0% to $2.9 million in 2026.
• Business Quant data shows TRDA's Accounts Payables at $2.9 million in Q1 2026, $2.3 million in Q4 2025, and $3.2 million in Q3 2025.